Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NYSEMKT
- Symbol: PFNX
Companies Related to Pfenex:
- Previous Close: $7.82
- 50 Day Moving Average: $8.29
- 200 Day Moving Average: $8.77
- 52-Week Range: $5.78 - $11.35
- Trailing P/E Ratio: 24.51
- Foreward P/E Ratio: -4.07
- P/E Growth: 3.53
- Market Cap: $183.13M
- Outstanding Shares: 23,418,000
- Beta: 4.65
What is Pfenex's stock symbol?
Pfenex trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PFNX."
Where is Pfenex's stock going? Where will Pfenex's stock price be in 2017?
3 brokers have issued 1-year price objectives for Pfenex's shares. Their forecasts range from $14.00 to $22.00. On average, they anticipate Pfenex's share price to reach $18.00 in the next year.
When will Pfenex announce their earnings?
Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Pfenex stock?
Pfenex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (16.53%), Dow Chemical Co. DE (7.56%), Perceptive Advisors LLC (3.90%), Marshall Wace LLP (1.25%), FMR LLC (1.17%) and State Street Corp (1.06%). Company insiders that own Pfenex stock include Bertrand C Liang, Chemical Co /De/ Dow, Henry W Jr Talbot, James C Gale, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc.
Who sold Pfenex stock? Who is selling Pfenex stock?
Pfenex's stock was sold by a variety of institutional investors in the last quarter, including Dow Chemical Co. DE, Franklin Resources Inc., FMR LLC and Allianz Asset Management AG. Company insiders that have sold Pfenex stock in the last year include Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc.
Who bought Pfenex stock? Who is buying Pfenex stock?
Pfenex's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Oxford Asset Management, Dimensional Fund Advisors LP, Renaissance Technologies LLC, State Street Corp and Marshall Wace LLP.
How do I buy Pfenex stock?
Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pfenex stock cost?
One share of Pfenex stock can currently be purchased for approximately $7.82.